Clinical Trials Logo

Clinical Trial Summary

Protectivity and Safety Following Recombinant Hepatitis B Vaccine with different source of Hepatitis B bulk compared to Hepatitis B (Bio Farma) vaccine in Indonesian Population


Clinical Trial Description

Protectivity and Safety Following Recombinant Hepatitis B Vaccine with different source of Hepatitis B bulk compared to Hepatitis B (Bio Farma) vaccine in Indonesian Population. Experimental, randomized, double blind, four arm parallel group study, lot to lot consistency study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03919578
Study type Interventional
Source PT Bio Farma
Contact
Status Completed
Phase Phase 2/Phase 3
Start date September 11, 2019
Completion date February 28, 2020

See also
  Status Clinical Trial Phase
Completed NCT05383560 - Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults Phase 2
Recruiting NCT01763268 - Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants Phase 2/Phase 3
Recruiting NCT05054621 - Immunogenicity of COVID-19 Vaccine on Heterologous Schedule Phase 2
Recruiting NCT05580159 - New Generation mRNA Booster Vaccine Against Emerging VOCs Phase 3
Active, not recruiting NCT05686161 - mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs Phase 3
Completed NCT04071379 - Comparison of Immunogenicity and Safety of DTP-HB-Hib (Bio Farma) With Pentabio® Vaccine Primed With Recombinant Hepatitis B Phase 3
Completed NCT01697007 - A Phase II Trial to Assess the Safety and Immunogenicity of DNA Priming Administered by the ID Zetajet® With or Without ID Derma Vax™ Electroporation Followed by IM MVA Boosting in Healthy Volunteers in Tanzania and Mozambique Phase 2
Completed NCT03680417 - Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children Phase 4
Completed NCT03722615 - Epidemiology of Congenital Cytomegalovirus in a High HIV Prevalence Setting, South Africa
Completed NCT01369927 - Shigella Sonnel O-SPC/rBRU Conjugate Vaccine Phase 1
Completed NCT04051268 - Immunogenicity and Safety of Vi-DT (Diphtheria Toxoid) Typhoid Conjugate Vaccine (Phase III) Phase 3
Recruiting NCT05115617 - Pregnant and Lactating Individuals & Newborns COVID-19 Vaccination Prospective Cohort Study
Not yet recruiting NCT05911087 - A Phase II/III Study to Evaluate the Immunogenicity and Safety and Efficacy of SWIM816 Vaccines for SARS-CoV-2 Phase 2/Phase 3
Completed NCT01092195 - Gardasil Vaccination in Post Stem Cell Transplant Patients Phase 1
Completed NCT01399853 - A Phase II Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants Phase 2
Completed NCT03460405 - Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine in Indonesian Adults, Adolescents, Children and Infants Phase 2
Completed NCT03681860 - EMaBS TB Vaccine Study Phase 1/Phase 2
Completed NCT04754698 - COVID-19 CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV/AIDS Phase 4
Completed NCT04015232 - Comparative Immunogenicity Study of Multiple Doses of Proposed Pegfilgrastim Biosimilar, INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects. Phase 1
Recruiting NCT05150834 - Gut Microbiota, the Potential Key to Modulating Humoral Immunogenicity of New Platform COVID-19 Vaccines